Cantor Fitzgerald Estimates Arcellx FY2025 Earnings

Arcellx, Inc. (NASDAQ:ACLX) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Arcellx in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company will post earnings of ($2.54) per share for the year. The consensus estimate for Arcellx’s current full-year earnings is ($1.58) per share.

ACLX has been the subject of a number of other research reports. Redburn Atlantic initiated coverage on Arcellx in a research report on Tuesday, October 8th. They set a “buy” rating and a $109.00 price target for the company. Robert W. Baird lifted their target price on shares of Arcellx from $77.00 to $106.00 and gave the company an “outperform” rating in a research report on Wednesday, November 6th. Bank of America boosted their price target on shares of Arcellx from $84.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Stifel Nicolaus raised their price objective on shares of Arcellx from $83.00 to $122.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Finally, Truist Financial upped their target price on shares of Arcellx from $87.00 to $136.00 and gave the stock a “buy” rating in a research report on Tuesday, November 12th. Thirteen analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $105.93.

Arcellx Stock Performance

NASDAQ:ACLX opened at $65.85 on Wednesday. Arcellx has a 52-week low of $47.88 and a 52-week high of $107.37. The stock has a fifty day moving average of $79.99 and a 200 day moving average of $76.52. The firm has a market capitalization of $3.56 billion, a price-to-earnings ratio of -92.75 and a beta of 0.33.

Arcellx (NASDAQ:ACLX) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.06. The firm had revenue of $26.03 million during the quarter, compared to the consensus estimate of $35.21 million. Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%.

Insiders Place Their Bets

In other news, Director Kavita Patel sold 33,763 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $104.14, for a total transaction of $3,516,078.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christopher Heery sold 3,301 shares of the firm’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $79.55, for a total value of $262,594.55. Following the completion of the sale, the insider now directly owns 35,517 shares in the company, valued at $2,825,377.35. The trade was a 8.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 63,416 shares of company stock valued at $6,242,800 in the last ninety days. Company insiders own 6.24% of the company’s stock.

Hedge Funds Weigh In On Arcellx

A number of hedge funds and other institutional investors have recently made changes to their positions in ACLX. State of New Jersey Common Pension Fund D purchased a new stake in shares of Arcellx in the 2nd quarter worth about $649,000. Renaissance Technologies LLC bought a new position in Arcellx in the second quarter worth about $1,494,000. Public Employees Retirement Association of Colorado purchased a new stake in Arcellx in the second quarter worth about $178,000. Great Point Partners LLC boosted its position in Arcellx by 64.0% during the 2nd quarter. Great Point Partners LLC now owns 492,000 shares of the company’s stock valued at $27,153,000 after acquiring an additional 192,000 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its holdings in shares of Arcellx by 53.3% during the 2nd quarter. Affinity Asset Advisors LLC now owns 460,000 shares of the company’s stock worth $25,387,000 after acquiring an additional 160,000 shares during the period. Institutional investors own 96.03% of the company’s stock.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).